Additionally, our previous findings suggest that not all TNBC patients may have active TGFβ-driven tumorigenic NDRG1, where NDRG1 could act as a tumor suppressor, making its inhibition undesirable in those patients5. Here, NDRG1 is linked to neoplasm.